- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06415318
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
May 10, 2024 updated by: ZHOU FANGJIAN, Sun Yat-sen University
A Single-center, Single-arm Clinical Study of TIP(Paclitaxel + Ifosfamide + Cisplatin) Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Penile cancer is a rare malignant tumor, which often occurs in the inner plate of the prepuce and glans.
Squamous cell carcinoma is the most common pathological type.
Lymph node metastasis is a crucial factor that leads to poor prognosis of penile cancer.
The 5-year OS of penile cancer patients without lymph node metastasis is 90%.
Still, it goes down sharply in patients with inguinal lymph node metastasis and pelvic lymph node metastasis, which is 50% and 0%, respectively.
Using neoadjuvant chemotherapy to treat patients with locally advanced penile cancer (T4, any N stage, or any T stage, N3) may improve their prognosis.
TIP (Paclitaxel + Ifosfamide + Cisplatin) regimen is the first-line neoadjuvant treatment recommended by NCCN guidelines.
PD-1 is an immune checkpoint molecule on the surface of T cells.
In recent years, immune checkpoint inhibitors targeting PD-1 have shown good efficacy in a variety of tumors.
Some phase II / III clinical trials have shown that PD-1 inhibitors can improve the prognosis of patients with lung squamous cell carcinoma, head and neck squamous cell carcinoma, and cervical cancer.
Previous studies have found that PD-L1 is highly expressed in 40% - 60% of penile cancer, suggesting that penile cancer patients may benefit from immunotherapy.
The management of penile cancer with lymph node metastasis is difficult, especially for the N2-3 stage.
This phase II study aims to explore an effective combination therapy for locally advanced penile cancer.
25 patients need to be enrolled.TIP & toripalimab will be administered every 21 days until surgery, evidence of disease progression, or onset of unacceptable toxicity.
Study Type
Interventional
Enrollment (Estimated)
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hui Han
- Phone Number: +86 13002018798
- Email: hanhui@sysucc.org.cn
Study Contact Backup
- Name: Ting Xue
- Phone Number: +86 18243057370
- Email: xueting1@sysucc.org.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Squamous cell carcinoma confirmed by histology or cytology;
- Clinical Stage is Locally advanced penile cancer (T4, any N stage; or any T stage, N3);
- No prior chemotherapy for newly diagnosed or relapsed patients or the time from the last chemotherapy to relapse should be longer than 12 months;
- There is at least one measurable lesion according to the solid tumor efficacy evaluation standard RECIST1.1;
- the Eastern Cooperative Oncology Group (ECOG) scored 0-2;
- Blood marrow function: Hemoglobin(Hb) >/= 80g/L; White blood cell count >/= 3.0x10^9/L; Neutrophil count >/= 1.5x10^9/L; Platelet count >/ = 100x10^9/L;
- Liver function: AST, ALT, ALP </= 2.5 ULN; Total bilirubin </= 1.5 ULN;
- Estimated survival >/= 12 months;
- No prior serious disease history of a systemic organ;
- The participant understands this study procedure and signs the informed consent.
Exclusion Criteria:
- Peripheral neuropathy degree >/=2 (affecting patient's function);
- Previously received any other experimental drug treatment within 4 weeks before enrollment;
- Patients with other cancer at present, or have other malignant tumor histories within the past 5 years. Except for (1) Cured skin non-malignant melanoma; (2) Curable tumor, including low-risk prostate cancer (T1a, Gleason score<6, PSA<0.5ng/ml), superficial bladder cancer and so on; (3) Other solid tumors have received radical treatment, and no recurrence or metastasis has been found at least 5 years;
- Other serious or poorly controlled concomitant diseases, including but not limited to (1) Severe or acute attack disease history of cardiovascular, liver, respiratory, kidney, blood, endocrine or neuropsychiatric system within 6 months; (2) Active infection history and needed antibiotic treatment within 2 weeks before enrollment; (3) Congestive heart failure (grade III-IV); (4) Unstable angina pectoris or myocardial infarction history within 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Neoadjuvant Therapy TIP (Paclitaxel + Ifosfamide + Cisplatin) & Toripalimab
Drug: Toripalimab 240mg, ivgtt, d1 Drug: Paclitaxel 175 mg/m2, ivgtt, d1 Drug: Cisplatin 25mg/m2·d, ivgtt, d1-3 Drug: Ifosfamide 1.2g/m2·d, ivgtt, d1-3
|
Paclitaxel + Ifosfamide + Cisplatin & Toripalimab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: 6 weeks
|
Objective Response Rate (ORR) based on RECIST 1.1 criteria.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pCR
Time Frame: 12 weeks
|
Percentage of Participants With Pathologically Complete Response
|
12 weeks
|
EFS
Time Frame: 2 months
|
Event-free survival, EFS
|
2 months
|
OS
Time Frame: 6 months
|
Overall Survival
|
6 months
|
Adverse events
Time Frame: 2 months
|
Number of participants with treatment-related adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
May 10, 2024
First Submitted That Met QC Criteria
May 10, 2024
First Posted (Actual)
May 16, 2024
Study Record Updates
Last Update Posted (Actual)
May 16, 2024
Last Update Submitted That Met QC Criteria
May 10, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Penile Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Penile Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Ifosfamide
Other Study ID Numbers
- B2024-043-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Penile Cancer
-
The Netherlands Cancer InstituteCompletedHead and Neck Cancer | Penile CancerNetherlands
-
Sun Yat-sen UniversityCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupTerminatedS0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)Penile CancerUnited States
-
Mayo ClinicRecruitingStage IV Penile Cancer AJCC v8 | Stage III Penile Cancer AJCC v8 | Metastatic Penile Squamous Cell Carcinoma | Unresectable Penile Squamous Cell CarcinomaUnited States
-
The Christie NHS Foundation TrustNot yet recruiting
-
European Organisation for Research and Treatment...CompletedPenile CancerFrance, United Kingdom, Poland, Belgium, Netherlands, Hungary
-
Queen Mary University of LondonUnknownCharacterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] (MRI-PET)Squamous Cell Carcinoma of the PenisUnited Kingdom
-
Latin American Cooperative Oncology GroupMerck Sharp & Dohme LLCCompleted
-
Latin American Cooperative Oncology GroupRoche Pharma AGCompletedPenile Squamous Cell CarcinomaBrazil
-
University Health Network, TorontoRecruitingMetastatic Cancer | Advanced Cancer | Penile CancerCanada
Clinical Trials on Paclitaxel + Ifosfamide + Cisplatin & Toripalimab
-
Memorial Sloan Kettering Cancer CenterCompletedBladder Cancer | Urethral CancerUnited States
-
Medical Research CouncilCompletedTesticular Germ Cell TumorUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Ovarian Cancer | Brain and Central Nervous System Tumors | Teratoma | Extragonadal Germ Cell TumorUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)TerminatedTesticular Germ Cell Tumor | Extragonadal Germ Cell TumorUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterCompletedTesticular Germ Cell Tumor | Ovarian CancerUnited States
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaChina
-
National Cancer Institute, SlovakiaCompleted
-
Jun GuoNot yet recruiting
-
Shanghai Jiao Tong University School of MedicineCompletedOral Cancer | Induction Chemotherapy | Programmed Cell Death 1 Inhibitor | Inductive TherapyChina
-
Ruijin HospitalRecruitingAdvanced Cervical CancerChina